Our Founder
Dr Pragya Sharma
Granlab began as a deeply personal mission for Dr Pragya Sharma, who holds a PhD in Structural Biochemistry from Queen's University Belfast. In 2018, whilst building on her scientific expertise and medical training from her studies at medical school in India, Pragya was moved to action by her grandmother's struggle with psoriasis.
For everybody.
For all of your body.
After exhausting all conventional treatments and experiencing serious side effects from steroid medications, her grandmother’s desperation for an alternative solution became the catalyst for Pragya to leverage her unique combination of biochemical research skills and medical knowledge.
What began as a passion project to help a loved one has evolved into Granlab's innovative approach to skin health. After recognising a critical gap in dermatological care, Pragya applied her specialised understanding of protein structures and biochemical pathways to develop a breakthrough formulation that addresses inflammatory skin conditions at the molecular level, without the harmful side effects of traditional steroid treatments.
Granlab’s formulation is steroid-free, and can be used on even the most sensitive parts of the body and has been developed to suit all types and colours of skin. Advanced LC-MS characterisation has identified more than 3,000 unique molecular signatures matching known bioactive compounds at confidence thresholds above 85%. After three months of using her treatment, Pragya’s grandmother’s skin was symptom-free, and Pragya was inspired to bring her remedy to the nearly 1 billion individuals around the world who suffer from skin diseases like psoriasis and eczema. Learn more about the science behind Granlab’s formulation here
Our Journey
Granlab was established in 2024. Our lab and team are based in Belfast, Northern Ireland, and we have already secured over £550,000 through equity-free grants and private investment.
We are on a journey to secure the remaining £650,000 to bring our over-the-counter, dermatology product range to the UK and EU markets.
We received S/EIS Advanced Assurance in October 2024, and have established a proof-of-concept qualitative study with patients across 5 countries, with 60% reporting continued absence of symptoms at 4-year follow-up assessments. Comprehensive clinical evidence will follow in the upcoming months.
If you are interested in investing in our concept or collaborating on our future, please get in touch here or subscribe to follow our journey
OUR MISSION
We are on a mission to revolutionise dermatological care for the nearly 1 billion people suffering from skin diseases globally.
Through groundbreaking research and innovation, we want to develop non-steroidal treatments that not only address symptoms but transform lives. Our GL-1 solution, represents the next generation in psoriasis care, embodying our commitment to scientific excellence and deep compassion.
We’re not just treating skin conditions; we’re restoring confidence, comfort and quality of life to millions worldwide.
